Peter Jüni to Treatment Outcome
This is a "connection" page, showing publications Peter Jüni has written about Treatment Outcome.
Connection Strength
0.248
-
Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial. Eur Heart J. 2019 04 14; 40(15):1226-1232.
Score: 0.029
-
Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ. 2017 Nov 07; 359:j4784.
Score: 0.027
-
Latest evidence on transcatheter aortic valve implantation vs. surgical aortic valve replacement for the treatment of aortic stenosis in high and intermediate-risk patients. Curr Opin Cardiol. 2017 Mar; 32(2):117-122.
Score: 0.025
-
BEST-When a Study Falls Short of Its Acronym. Am J Cardiol. 2015 Sep 15; 116(6):995.
Score: 0.022
-
Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. Trials. 2021 Mar 22; 22(1):224.
Score: 0.008
-
Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost. 2020 11; 18(11):2958-2967.
Score: 0.008
-
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019 11 19; 140(21):1693-1702.
Score: 0.008
-
Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. EuroIntervention. 2019 Aug 09; 15(6):e539-e546.
Score: 0.007
-
Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. Circ Cardiovasc Interv. 2019 08; 12(8):e008024.
Score: 0.007
-
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). Eur Heart J. 2019 07 01; 40(25):2070-2085.
Score: 0.007
-
Fractional Flow Reserve and Quality-of-Life Improvement After Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. Circulation. 2018 10 23; 138(17):1797-1804.
Score: 0.007
-
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet. 2018 09 01; 392(10149):737-746.
Score: 0.007
-
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. EuroIntervention. 2018 Aug 20; 14(6):692-699.
Score: 0.007
-
Homograft Versus Conventional Prosthesis for Surgical Management of Aortic Valve Infective Endocarditis: A Systematic Review and Meta-analysis. Innovations (Phila). 2018 May/Jun; 13(3):163-170.
Score: 0.007
-
Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EuroIntervention. 2018 01 20; 13(13):1565-1573.
Score: 0.007
-
Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. EuroIntervention. 2018 01 20; 13(13):1574-1586.
Score: 0.007
-
Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation). Circulation. 2018 01 30; 137(5):480-487.
Score: 0.007
-
A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study. PLoS One. 2017; 12(8):e0182632.
Score: 0.007
-
Quantitative sensory tests fairly reflect immediate effects of oxycodone in chronic low-back pain. Scand J Pain. 2017 10; 17:107-115.
Score: 0.007
-
Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort. Eur Heart J Acute Cardiovasc Care. 2018 Sep; 7(6):522-531.
Score: 0.006
-
Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis. EuroIntervention. 2017 Apr 07; 12(18):e2170-e2176.
Score: 0.006
-
Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. Eur Heart J. 2017 04 07; 38(14):1069-1080.
Score: 0.006
-
Surgical versus conservative treatment for lumbar disc herniation: a prospective cohort study. BMJ Open. 2016 12 21; 6(12):e012938.
Score: 0.006
-
A systematic review and meta-analysis of in situ versus composite bilateral internal thoracic artery grafting. J Thorac Cardiovasc Surg. 2017 05; 153(5):1108-1116.e16.
Score: 0.006
-
Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents. EuroIntervention. 2014 Jan 22; 9(9):1076-84.
Score: 0.005